Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 145
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1.25M | 2.03M | 1956 |
| Mr. Paul J. Mellett Jr. | Senior VP of Finance & Administration and CFO | 666.84k | 529.98k | 1955 |
| Dr. Yat Sun Or Ph.D. | Senior VP of Research & Development and Chief Scientific Officer | 729.31k | 424.85k | 1952 |
| Mr. Nathaniel S. Gardiner J.D. | Consultant | 672.67k | 49.14k | 1954 |
| Mr. Brendan Luu | Senior Vice President of Business Development | 622.86k | N/D | 1975 |
| Ms. Jennifer Viera | Senior Director of Investor Relations & Corporate Communications | N/D | N/D | N/D |
| Mr. Matthew P. Kowalsky J.D. | Chief Legal Officer | N/D | N/D | 1973 |
| Ms. Tara Lynn Kieffer Ph.D. | Senior Vice President of New Product Strategy & Development | 496.85k | N/D | 1978 |
| Dr. Scott T. Rottinghaus M.D. | Senior VP & Chief Medical Officer | 616.73k | N/D | 1974 |
Descripción
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Enanta Pharmaceuticals, Inc. a partir del 1 de mayo de 2024 es 6. Las puntuaciones principales son Auditoría: 3; Junta: 4; Derechos del accionista: 8; Compensación: 7.
